Immunovirology and Host–Pathogen Interactions - looking for collaborators and Post docs

Immunovirology and Host–Pathogen Interactions

Expert: Prof. Marie Larsson
Affiliation: Linköping University, Sweden
Field: Immunology, Virology, Molecular Medicine

Expertise Summary:
Professor Marie Larsson is a leading researcher in immunovirology at Linköping University’s Medical Faculty. As Director of the Medical Inflammation and Infection Center (MIIC) and Head of the Molecular Medicine and Virology Division, she investigates how viruses interact with and modulate human immune cells and tissues. Her work focuses on the immunomodulatory effects of HIV-1 on dendritic cells and T cells, as well as the early host immune responses to RNA viruses such as coronaviruses, RSV, and Dengue virus.

Her research bridges virology, immunology, and translational medicine, aiming to elucidate mechanisms of viral immune evasion and pathogenesis that inform vaccine and therapeutic development.

Key Areas of Expertise:

• Immunomodulation by HIV-1 and RNA viruses

• Human dendritic cell and T-cell biology

• Host–pathogen interactions and immune signaling

• Viral infection of respiratory and mucosal tissues

• Translational research on antiviral and immunotherapeutic strategies

Experience and Recognition:

• Director, Medical Inflammation and Infection Center (MIIC), Linköping University

• Former researcher at The Rockefeller University and New York University Langone Medical Center

• Reviewer for Swedish Research Council, Marie Skłodowska-Curie grants, and Dutch Cancer Society

• Recipient of the LiU Leadership Prize and Eric K. Fernströms Award

• Author of 140+ peer-reviewed publications (11,000+ citations; H-index: 53, i10-index: 109, Google Scholar, May 2025)

Publications:
NCBI Bibliography

Professional Profiles:

• Marie Larsson – Linköping University Marie Larsson - Linköpings universitet

Collaboration Interests:
Open to collaboration within Marie Skłodowska-Curie Actions in the areas of virus–host interactions, immunopathology, and antiviral immunotherapy development.